Paradigms for the development of transformative medicines-lessons from the EGFR story
Ann Oncol
.
2022 May;33(5):556-560.
doi: 10.1016/j.annonc.2022.02.005.
Epub 2022 Feb 18.
Authors
W Pao
1
,
Y A Nagel
2
Affiliations
1
F. Hoffmann-La Roche Ltd., Basel, Switzerland. Electronic address: william.pao@roche.com.
2
F. Hoffmann-La Roche Ltd., Basel, Switzerland.
PMID:
35189267
DOI:
10.1016/j.annonc.2022.02.005
No abstract available
Publication types
Editorial
MeSH terms
ErbB Receptors* / genetics
Humans
Substances
EGFR protein, human
ErbB Receptors